analysis that included risk stratification according to DIPSS. 8 The lone PMF patient which had both ASXL1 and TET2 mutations was diagnosed with PV at age 67 years after a 12-year history of unexplained leukocytosis. He was treated with phlebotomy and hydroxyurea and started to develop progressive splenomegaly by age 71, and was ultimately diagnosed with post-PV MF by age 73. At the time, he was enrolled in a thalidomide therapy-based clinical trial and developed pulmonary extramedullary hematopoiesis by August 2005 and ultimately died in October 2005, without progressing into AML. The three ASXL1 mutated CMML cases were alive after 40, 34 and 12 months from time of mutation analysis and none of them had progressed to acute leukemia; karyotype was normal in two of the patients and showed isolated trisomy 8 in one.
The current study illustrates a number of points. First, it provides incidence estimates for EZH2 and ASXL1 mutations in a relatively large cohort of CMML and MF cases. The results suggest that ASXL1 mutations are as frequent as TET2 mutations and the two were not necessarily mutually exclusive, although their co-occurrence was less likely in MF, as compared with CMML ( Figures 1c and d) . The biological consequence of this particular observation is currently not clear and will need to be investigated in future functional studies. Regardless, the current study underscores the profound lack of disease specificity and mutual exclusivity shown by recently described MPNassociated mutations and our observations do not support the suggestions from recent studies regarding the association of ASXL1 or EZH2 mutations with poor clinical outcome. However, a larger number of patients followed for a longer period of time is needed to validate these preliminary observations.
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ICSBP promoter methylation in myelodysplastic syndromes and acute myeloid leukaemia Interferon consensus sequence-binding protein (ICSBP) was first described as a negative regulator of interferon-inducible genes, implying an important role in interferon (IFN) g signalling and immune response.
1,2 Later, ICSBP-deficient mice were shown to develop a disease resembling human chronic myeloid leukaemia, 3, 4 suggesting a tumour suppressor function of ICSBP. ICSBP functions as a molecular switch factor directing the differentiation of bi-potential myeloid precursors toward the monocytic lineage, 5 possibly by forming heterodimeric complexes with PU.1. 6 Moreover, ICSBP has pro-apoptotic properties, 7 and modulates proliferation of leukaemic cells, requiring the chemokines CCL6 and CCL9. 8, 9 Despite these important roles of ICSBP shown in the differentiation of haematopoietic cells, relatively less is known about its inactivation in human myeloid malignancies. Patients with chronic myeloid leukaemia and acute myeloid leukaemia (AML) show reduced ICSBP-mRNA expression.
10 Furthermore, reduced ICSBP expression correlates with poor cytogenetic response to IFNa treatment. 11 Gene
Letters to the Editor expression profiling of CD34 þ haematopoietic stem/progenitor cells revealed that therapy-related AML with loss of chromosome 5 or deletion of 5q (À5/del(5q)), in addition to upregulation of growth-promoting genes, had no expression of ICSBP. 12 Using a novel approach to determine the methylation status of candidate tumour suppressor genes called methyl-binding (MB)-PCR, the ICSBP gene was identified as a target of hypermethylation in AML. 13 To obtain a first estimation of whether and to what extent ICSBP transcription is downregulated and whether there is an association between downregulation of ICSBP and recurrent cytogenetic aberrations of myelodysplastic syndrome (MDS) and AML, we screened the PubMed GEO database (http:// www.ncbi.nlm.gov/geo/accession number GSE425/8653, Supplementary Figure S1a and b) . 14, 15 By gene-expression data mining, a significant downregulation of ICSBP in AML with t(15;17) and with t(8;21), and a tendency of ICSBP downregulation in -7/del(7q) was found (Supplementary Figure S1c) . Furthermore, an ICSBP downregulation was published for therapy-induced AML with -5/del(5q). 12 To substantiate these findings, we investigated a cohort of 100 patients with myeloid malignancies that had been characterized cytogenetically (Supplementary Table S3 lead to a loss of wild-type function in in vitro and in vivo models. 5, 6, 16 We analysed these exons by direct sequencing in 68 patients from whom material was available (Supplementary Materials and Methods). We found unaltered sequences in almost all analysed patients. Clearly, we cannot rule out that mutations in exons 4, 5 and 6 might also play a role. Two MDS patients with del(5q) harboured the silent single-nucleotide substitution c.864C4T; p.Phe288Phe in exon 7 (Supplementary  Table S1 ). It seemed unlikely that this nucleotide substitution caused downregulation of ICSBP. Furthermore, we investigated the frequency of deletions of the ICSBP chromosomal locus 16q24.1. A dual-colour fluorescence in situ hybridisation probe to enable detection of micro-deletions was generated (Supplementary Materials and Methods and Supplementary Figure S2 ). In 26 patients from different cytogenetic subgroups, material was available, but no deletion or structural rearrangement was identified (Supplementary Table S1 ). To extend these analyses, we carried out an in silico ICSBP deletion screening in 69 MDS and 112 AML patients. [17] [18] [19] Loss of one copy of the ICSBP locus in 16q24.1 was seen in 5% of the analysed AML patients (Supplementary Figure S3 ). All of them had a complex karyotype.
In Table 1 and Supplementary Table S2 , the methylation status of the ICSBP promoter, as determined by methylationspecific PCR (MSP; Figure 1a and Supplementary Materials and Methods) is summarised. Overall, 12 of 59 (20%) patients with MDS, 3 of 12 (25%) patients with de novo AML, and 8 of 29 (28%) patients with secondary AML (Table 1) presented the methylated MSP product and were declared as methylated positive (Figure 1b) . No methylation was seen in the eight healthy controls. Male patients had a significantly higher chance for ICSBP promoter methylation than female patients (OR ¼ 2.9 (0.34; 8.78); P ¼ 0.043). Both gender groups exhibit comparable age pattern. ICSBP methylation was found in all cytogenetic subgroups of MDS and AML except for cytogenetically normal (CN) MDS. Accordingly, the chance for ICSBP methylation was 3.57-fold higher in the patients with aberrant karyotype (24%) compared with CN patients (10%)(OR ¼ 3.57 (0.597; 68.658); P ¼ 0.24). This is true both for patients with MDS and with secondary AML (22 versus 0% for MDS; 30 versus 17% for secondary AML)(Supplementary Table S2 ). In more detail, patients carrying a single chromosomal aberration, for example, del(5q), -7/del(7q) or trisomy 8, presented a higher ICSBP methylation rate than CN patients or patients with complex karyotype. Considering all cytogenetic subgroups, the highest ICSBP promoter methylation was observed in secondary AML (Supplementary Table S2 , Figure 1c) , with a trend in increasing ICSBP methylation in the CN patient groups (0% MDS versus 17% secondary AML), and in the trisomy 8 patient groups (29% MDS versus 50% secondary AML) (Supplementary Table S2 ). In conclusion, a substantial proportion of patients with MDS and AML showed ICSBP promoter methylation, particularly those with secondary AML.
To verify the results of MSP, we pyrosequenced fragments of the ICSBP CpG island (Figure 1a and Supplementary Materials and Methods) in 15 patients presenting a methylated MSP product and eight patients with an unmethylated MSP product (Figure 1d and Supplementary Figure S4) . Quantification of the CpG methylation status correlated strongly with the MSP results. Patients with methylated MSP products had significantly higher rates of CpG methylation than patients with unmethylated MSP products (P ¼ 0.00019). Interestingly, all patients with an unmethylated MSP product showed a very low percentage of methylated fragment 01 (B5%; Figure 1d ) in pyrosequencing. Calculating a cut-off line by the mean plus 2 s.d., that is, 6.44%, Letters to the Editor 13 out of 15 patients with methylated MSP product had higher methylation values of the 5 0 region of ICSBP compared with the unmethylated patients. Furthermore, ICSBP expression of 14 patients presenting a methylated MSP product was analysed by real-time reverse-transcription PCR (Supplementary Materials and Methods). ICSBP expression levels were lower in patients with ICSBP promoter methylation than in the relevant controls (Figure 1d ), reinforcing that CpG island methylation may lead to a downregulation of ICSBP in myeloid malignancies.
To determine the functional consequences of ICSBP promoter methylation in myeloid malignancies, we investigated ICSBP promoter methylation in the AML cell lines F-36P, HL-60, Kasumi-1, ME-1, MV4-11, NB-4 and U937 (Supplementary Figure S5) . As Kasumi-1 presented only the methylated MSP product and lacked ICSBP protein, this cell line was chosen for further functional analyses. After treatment with the demethylating agent 5-aza-2 0 -deoxycytidine (DAC), ICSBP was demethylated as demonstrated by an MSP (Figure 2a) leading to ICSBP Pyrosequencing in % P 3 P 8 P 2 0 P 3 9 P 3 5 P 7 0 P 7 9 P 9 6 c t r l B M P 1 0 P 1 9 P 4 1 P 6 8 P 7 4 P 9 2 c t r l P B Letters to the Editor re-expression (Figures 2b and c) . The ICSBP expression was further increased by addition of IFNg (P ¼ 0.0301, Figure 2b ), which is also needed for the ICSBP protein function. 20 Although DAC treatment induced growth inhibition (Figure 2d ) and apoptosis (P ¼ 0.0252, Figure 2e ), the addition of IFNg had no obvious effects on proliferation or apoptosis induction.
However, ICSBP is known to be involved in the regulation of distinct apoptotic pathways and sensitises cells for apoptosis induced by chemotherapeutic agents like etoposide, 7 a topoisomerase-II inhibitor inducing DNA double-strand breaks. As described above, ICSBP re-expression alone, either by DAC treatment or by ectopic expression after ICSBP transfection had no dramatic effect on apoptosis in contrast to untreated cells (Figures 3a and b) . To induce apoptosis, cells were treated with etoposide for 18 h. The rate of apoptosis increased 10.5-fold after addition of etoposide (P ¼ 0.0035, n ¼ 3). Cells expressing high levels of ICSBP, induced by DAC and IFNg treatment, still presented a 2.7-fold higher rate of apoptosis after addition of etoposide compared with cells treated only with DAC and etoposide (P ¼ 0.0174, n ¼ 3, Figure 3a) . Moreover, to rule out that global hypomethylation by DAC treatment and not the ICSBP re-expression, apoptosis was measured in transfected cells expressing ICSBP ectopically (Figure 3d) . Again, the rate of etoposide-induced apoptosis was 5.9-fold higher in ICSBPtransfected and IFNg-treated cells after addition of etoposide than in ICSBP-transfected cells without etoposide (P ¼ 0.0485; Figure 3b ). As demonstrated by caspase-3 cleavage, caspase-3 is involved in ICSBP-induced apoptosis (Figures 3c and d) . This is in agreement with previous reports on caspase-3 cleavage by etoposide treatment in U937 cells overexpressing ICSBP. In conclusion, we showed that the promoter of ICSBP, an important regulator of differentiation and survival of haematopoietic cells, 21 was methylated in a substantial proportion of patients with MDS and AML. ICSBP promoter methylation seems to be the main mechanism of ICSBP inactivation in myeloid malignancies and may be functionally important for accumulation of chromosome aberrations during leukemic progression. We also demonstrate that resistance to DNA damage-induced apoptosis mediated by ICSBP promoter hypermethylation can be overcome by treatment with DAC and may re-sensitize myeloid malignancies for chemotherapy with topoisomerase inhibitors.
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